SITE003-0158

SITE003 (CAN) › SITE003-0158

SITE003-0158

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2026-03-16

enrolled

AEs

1

Serious

0

Dropout signal

–

Adverse events

1

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-13 (study day 150); relationship: NOT RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.